眼科用ドラッグデリバリーシステムの世界市場：洞察、競合情勢、市場予測：2030年

世界の眼科用ドラッグデリバリーシステムの市場規模は、2022年に146億6,932万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に7.39%のCAGRで拡大し、2030年には223億7,310万米ドルに達する見込みです。眼科用ドラッグデリバリーシステム市場は、世界の高齢者人口の増加、白内障、緑内障、眼アレルギー、感染症などの様々な眼疾患や眼科疾患の症例の増加、眼科用ドラッグデリバリーシステム分野での世界の臨床試験や製品開発活動の増加などにより、プラスの市場成長を遂げており、予測期間中（2024年～2030年）に眼科用ドラッグデリバリーシステム市場の収益成長が期待されています。

眼科用ドラッグデリバリーシステム市場の成長の主な要因の1つは、白内障や緑内障などの眼疾患、近視や老眼などの屈折異常の世界の有病率の上昇です。例えば、世界保健機関（WHO）2022年版によると、近視または遠視の有病率は世界全体で22億人という驚異的な数字となっており、そのうち約半数が視力障害を予防できた可能性があります。

同じ情報源によると、2020年における未対処の白内障と緑内障の有病率は、世界でそれぞれ9,400万人と770万人です。また、近視や老眼などの屈折異常も今後数年間で増加すると言われています。国際近視研究所（2023年）によると、現在、世界の30％が近視であり、2050年までに近視人口は50％に増加し、50億人に達すると言われています。

当レポートでは、世界の眼科用ドラッグデリバリーシステム市場について調査し、市場の概要とともに、技術別、適応症別、剤形別、投与経路別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 眼科用ドラッグデリバリーシステム市場レポートのイントロダクション

第2章 眼科用ドラッグデリバリーシステム市場のエグゼクティブサマリー

第3章 規制分析

第4章 眼科用ドラッグデリバリーシステム市場の主な要因分析

• 眼科用ドラッグデリバリーシステム市場の促進要因
• 眼科用ドラッグデリバリーシステム市場の抑制要因と課題
• 眼科用ドラッグデリバリーシステム市場の機会

第5章 眼科用ドラッグデリバリーシステム市場におけるポーターのファイブフォース分析

第6章 眼科用ドラッグデリバリーシステム市場に対するCOVID-19の影響分析

第7章 眼科用ドラッグデリバリーシステム市場の概要

• 技術別
• 適応症別
• 剤形別
• 投与経路別
• 地域別

第8章 眼科用ドラッグデリバリーシステム市場の企業と製品プロファイル

• Ocular Therapeutix Inc.
• Allergan plc.
• Santen Pharmaceutical Co. Ltd.
• Envisia Therapeutics
• pSivida
• Clearside Biomedical
• Oculis Pharma
• Valeant Pharmaceuticals
• Aptar Group, Inc.
• Graybug Vision Inc.
• Alimera Sciences
• Eyegate Pharma
• Vision Ophthalmology Group GmbH
• URSAPHARM Arzneimittel GmbH
• AbbVie Inc.
• Taiwan Liposome Company, Ltd.
• Novartis
• Amorphex Therapeutics
• Eyenovia, Inc.
• iVeena Delivery Systems

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Ocular Drug Delivery System Market
• Table 3: Ocular Drug Delivery System Market Analysis in Global (2021-2030)
• Table 4: Ocular Drug Delivery System Market Analysis in Global by Technology (2021-2030)
• Table 5: Ocular Drug Delivery System Market Analysis in Global by Indication (2021-2030)
• Table 6: Ocular Drug Delivery System Market Analysis in Global by Formulation (2021-2030)
• Table 7: Ocular Drug Delivery System Market Analysis in Global by Route of Administration (2021-2030)
• Table 8: Ocular Drug Delivery System Market Analysis in Global by Geography (2021-2030)
• Table 9: Ocular Drug Delivery System Market Analysis in North America (2021-2030)
• Table 10: Ocular Drug Delivery System Market Analysis in North America by Country (2021-2030)
• Table 11: Ocular Drug Delivery System Market Analysis in the US (2021-2030)
• Table 12: Ocular Drug Delivery System Market Analysis in Canada (2021-2030)
• Table 13: Ocular Drug Delivery System Market Analysis in Mexico (2021-2030)
• Table 14: Ocular Drug Delivery System Market Analysis in Europe (2021-2030)
• Table 15: Ocular Drug Delivery System Market Analysis in Europe by Country (2021-2030)
• Table 16: Ocular Drug Delivery System Market Analysis in France (2021-2030)
• Table 17: Ocular Drug Delivery System Market Analysis in Germany (2021-2030)
• Table 18: Ocular Drug Delivery System Market Analysis in the UK (2021-2030)
• Table 19: Ocular Drug Delivery System Market Analysis in Italy (2021-2030)
• Table 20: Ocular Drug Delivery System Market Analysis in Spain (2021-2030)
• Table 21: Ocular Drug Delivery System Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Ocular Drug Delivery System Market Analysis in Asia-Pacific (2021-2030)
• Table 23: Ocular Drug Delivery System Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 24: Ocular Drug Delivery System Market Analysis in China (2021-2030)
• Table 25: Ocular Drug Delivery System Market Analysis in Japan (2021-2030)
• Table 26: Ocular Drug Delivery System Market Analysis in India (2021-2030)
• Table 27: Ocular Drug Delivery System Market Analysis in Australia (2021-2030)
• Table 28: Ocular Drug Delivery System Market Analysis in South Korea (2021-2030)
• Table 29: Ocular Drug Delivery System Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 30: Ocular Drug Delivery System Market Analysis in the Rest of the World (2021-2030)
• Table 31: Ocular Drug Delivery System Market Analysis in the Rest of the World by Region (2021-2030)
• Table 32: Ocular Drug Delivery System Market Analysis in the Middle East (2021-2030)
• Table 33: Ocular Drug Delivery System Market Analysis in Africa (2021-2030)
• Table 34: Ocular Drug Delivery System Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Ocular Drug Delivery System Market
• Figure 3: Ocular Drug Delivery System Market Analysis in Global (2021-2030)
• Figure 4: Ocular Drug Delivery System Market Analysis in Global by Technology (2021-2030)
• Figure 5: Ocular Drug Delivery System Market Analysis in Global by Indication (2021-2030)
• Figure 6: Ocular Drug Delivery System Market Analysis in Global by Formulation (2021-2030)
• Figure 7: Ocular Drug Delivery System Market Analysis in Global by Route of Administration (2021-2030)
• Figure 8: Ocular Drug Delivery System Market Analysis in Global by Geography (2021-2030)
• Figure 9: Ocular Drug Delivery System Market Analysis in North America (2021-2030)
• Figure 10: Ocular Drug Delivery System Market Analysis in North America by Country (2021-2030)
• Figure 11: Ocular Drug Delivery System Market Analysis in the US (2021-2030)
• Figure 12: Ocular Drug Delivery System Market Analysis in Canada (2021-2030)
• Figure 13: Ocular Drug Delivery System Market Analysis in Mexico (2021-2030)
• Figure 14: Ocular Drug Delivery System Market Analysis in Europe (2021-2030)
• Figure 15: Ocular Drug Delivery System Market Analysis in Europe by Country (2021-2030)
• Figure 16: Ocular Drug Delivery System Market Analysis in France (2021-2030)
• Figure 17: Ocular Drug Delivery System Market Analysis in Germany (2021-2030)
• Figure 18: Ocular Drug Delivery System Market Analysis in the UK (2021-2030)
• Figure 19: Ocular Drug Delivery System Market Analysis in Italy (2021-2030)
• Figure 20: Ocular Drug Delivery System Market Analysis in Spain (2021-2030)
• Figure 21: Ocular Drug Delivery System Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Ocular Drug Delivery System Market Analysis in Asia-Pacific (2021-2030)
• Figure 23: Ocular Drug Delivery System Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 24: Ocular Drug Delivery System Market Analysis in China (2021-2030)
• Figure 25: Ocular Drug Delivery System Market Analysis in Japan (2021-2030)
• Figure 26: Ocular Drug Delivery System Market Analysis in India (2021-2030)
• Figure 27: Ocular Drug Delivery System Market Analysis in Australia (2021-2030)
• Figure 28: Ocular Drug Delivery System Market Analysis in South Korea (2021-2030)
• Figure 29: Ocular Drug Delivery System Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 30: Ocular Drug Delivery System Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Ocular Drug Delivery System Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 32: Ocular Drug Delivery System Market Analysis in the Middle East (2021-2030)
• Figure 33: Ocular Drug Delivery System Market Analysis in Africa (2021-2030)
• Figure 34: Ocular Drug Delivery System Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Market Opportunities
• Figure 38: PORTER's Five Force Analysis

Ocular Drug Delivery System Market By Technology (Implantable, Particulate, And Others), By Indication (Glaucoma, Cataract, Dry Eyes, Eye Allergy, And Others), By Formulation (Solution-Based, Suspension Based, Emulsion-Based, Others), By Route Of Administration (Topical, Intraocular, Intravitreal, Intracameral, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the rising burden of geriatric population globally, increase in the prevalence of various eye disorders and ophthalmic problems such as cataract, glaucoma, eye allergies, infections, among others and the increasing product development activities in the ocular drug delivery system across the globe.

The global ocular drug delivery system market was valued at USD 14,669.32 million in 2022 and is likely to register a CAGR of 7.39% during the forecast period from 2024 to 2030 to reach USD 22,373.10 million by 2030. The Ocular Drug Delivery System market is observing optimistic market growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and ophthalmic diseases such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ocular drug delivery systems arena across the globe is further expected to result in appreciable revenue growth of the Ocular Drug Delivery System market during the forecast period (2024-2030).

Ocular Drug Delivery System Market Dynamics:

One of the main factors for the growth of the ocular drug delivery system market is the increasing prevalence of eye disorders such as cataracts and glaucoma, and refractive errors like myopia, and presbyopia, among others globally. For instance, according to the World Health Organization (WHO) 2022, the prevalence of population having near or distant vision impairment stands at a staggering figure of 2.2 billion globally, of which almost half of the affected people could have prevented vision impairment.

According to the same source, the prevalence rate of unaddressed cataracts and glaucoma in the year 2020 were 94 million and 7.7 million globally respectively. The number of refractive errors such as myopia and presbyopia is also said to increase in the upcoming years. As per the International Myopia Institute (2023), 30% of the world is currently myopic and by 2050, the number of myopic people is said to grow to 50%, accounting for five billion.

Furthermore, as per the World Glaucoma Association 2022, the worldwide prevalence reported in 2020 was estimated to be approximately 79.6 million. As per the same source, the number is likely to increase to 111.8 million individuals by 2040.

Therefore, due to the presence of a large patient pool associated with ophthalmic problems and vision impairments worldwide, the demand for ocular drug delivery systems is expected to rise substantially during the forecast period from 2024-2030.

However, certain side effects associated with the use of eye drops, gels, ointments, complications involved in ocular surgeries, and others may act as restraints for the ocular drug delivery system market growth.

The ocular drug delivery systems market was moderately impacted during the COVID-19 pandemic. During the initial stage of the pandemic, the sale and distribution of various eye-related drugs suffered a downfall owing to the imposition of strict lockdown rules, and disruption in the manufacturing, and supply of the drugs. Also, during the pandemic, COVID-19 patients were given more preference in terms of diagnosis and treatment, and this led to a decreased number of diagnoses and treatments for various ophthalmic conditions such as cataracts, dry eyes, glaucoma, macular degeneration, conjunctivitis, and others which in turn lead to the decreased demand for ocular drug delivery system, negatively impacting the growth of ocular drug delivery systems market. However, with the ease of lockdown restrictions, the upturn of resources, and the supply chain, the administration of the vaccine to the public, with the increasing number of diagnoses for ocular diseases, the demand for ocular drug delivery systems increased and is expected to grow during the forecast period from 2022 - 2028.

Ocular Drug Delivery System Market Segment Analysis:

Ocular Drug Delivery System market by technology (implantable, particulate, and others), indication (glaucoma, cataract, dry eyes, eye allergy, and others), formulation (solution-based, suspension-based, emulsion-based, others), route of administration (topical, intraocular, intravitreal, intracameral, and others) and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the formulation segment of the ocular drug delivery system market, the solution-based ocular drug delivery system is expected to have a significant revenue share in the year 2023. This can be attributed to their wide applicability, compatibility, and easy mode of administration, along with the rising research and developmental activities in the solution-based Ocular Drug Delivery System segment during the forecast period.

The solution-based ocular drug delivery system majorly includes all the drug types in the solution form, majorly comprising eye drops. The solution drug delivery systems mainly contain a saline base which can provide moisture for the eyes and can also help to pull the redness out. They also contain medicinal ingredients in cases of eye drops recommended for vision impairments such as refractive errors and others such as glaucoma, cataract, etc. A wide variety of diseases such as conjunctivitis, glaucoma, keratitis, eye allergies, and also before cataract surgery, corneal surgery, and others can be treated using solution-based drug deliverables, thus providing a wide end-user base and application opportunities.

In April 2022, Sandoz, a Novartis division, announced the US launch of the generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie's COMBIGAN, to lower eye pressure in patients with ocular hypertension.

Therefore, owing to the interplay of all the aforementioned factors, it is expected that the demand for solution-based drug delivery systems shall increase in the overall ocular drug delivery system market during the forecast period from 2022-2028.

North America is expected to dominate the overall Ocular Drug Delivery System Market:

Among all the regions, North America is expected to dominate the global Ocular Drug Delivery System market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This domination is due to the rising prevalence of eye disorders such as cataract, diabetic retinopathy, and others, the increasing geriatric population, and the rising product launches in North America, among others.

According to the National Eye Institute (2023), the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases in 2020, and the cases are expected to reach 11.3 million and 38 million, respectively, by 2030. The American Association of Ophthalmology states that cataract is the major cause of visual impairment worldwide, and geriatric ophthalmic issues are emerging as prime factors in other developing countries apart from Noth America.

Along with the growing patient population associated with eye disorders, product development activities in North America are further expected to bolster the demand for ocular drug delivery systems in the upcoming years.

In October 2019, Sun Pharmaceutical Industries Limited launched CEQUA for the Treatment of Dry Eye Disease in the U.S., which is a solution of 0.09% for topical ophthalmic use and is the first and only approved cyclosporine treatment delivered with NCELL(TM) technology.

Therefore, the interplay of various factors such as the presence of a large patient population, as well as product development activities such as product launches by key market players in the region is expected to boost the North America Ocular Drug Delivery System market during the forecast period.

Ocular Drug Delivery System Market Key Players:

Some of the key market players operating in the Ocular Drug Delivery System Market include Ocular Therapeutix Inc., Allergan plc., Santen Pharmaceutical Co. Ltd., Envisia Therapeutics, pSivida, Clearside Biomedical, Oculis Pharma, Valeant Pharmaceuticals, Aptar Group, Inc., Graybug Vision Inc., Alimera Sciences, Eyegate Pharma, Vision Ophthalmology Group GmbH, URSAPHARM Arzneimittel GmbH, AbbVie Inc., Taiwan Liposome Company, Ltd., Novartis, Amorphex Therapeutics, Eyenovia, Inc., iVeena Delivery Systems, and others.

Recent Developmental Activities in Ocular Drug Delivery System Market:

In September 2022, the U.S. Food and Drug Administration approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD). Byooviz is also approved to treat macular edema (fluid build-up) following retinal vein occlusion (blockage of veins in the retina) and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness).

In April 2022, Alcon announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products - Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Drops; having HydroBoost® Technology providing extra moisture for patients with sensitive dry eyes.

In September 2020, Bausch Health Companies Inc., Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. announced the FDA approval for its Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes.

Key Takeaways from the Ocular Drug Delivery System Market Report Study

• Market size analysis for current Ocular Drug Delivery System Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Ocular Drug Delivery System market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Ocular Drug Delivery System market.
• Various opportunities available for the other competitor in the Ocular Drug Delivery System Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current Ocular Drug Delivery System Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Ocular Drug Delivery System market growth in the coming future?

Target Audience who can be benefited from this Ocular Drug Delivery System Market Report Study

• Ocular Drug Delivery System products providers
• Research and development organizations
• Ocular Drug Delivery System-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Ocular Drug Delivery Systems
• Various end users who want to know more about the Ocular Drug Delivery System market and the latest innovations in the Ocular Drug Delivery System market.

Frequently Asked Questions for the Ocular Drug Delivery System Market:

1. What are ocular drug delivery systems?

Ocular Drug Delivery Systems can be used in conjunction with ophthalmic devices, applied directly to the eye's surface, or administered near or inside the eye. These ocular delivery techniques are employed to treat various vision-related illnesses and disorders.

2. What is the global market for Ocular Drug Delivery Systems?

The global ocular drug delivery system market was valued at USD 14,669.32 million in 2022 and is likely to register a CAGR of 7.39% during the forecast period from 2024 to 2030 to reach USD 22,373.10 million by 2030.

3. What are the drivers for the global Ocular Drug Delivery System market?

The Ocular Drug Delivery System market is witnessing positive growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and ophthalmic diseases such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ocular drug delivery systems arena across the globe is further expected to result in appreciable revenue growth of the Ocular Drug Delivery System market during the forecast period (2024-2030).

4. Who are the key players operating in the global Ocular Drug Delivery System market?

Some of the key market players operating in the Ocular Drug Delivery System market include Ocular Therapeutix Inc., Allergan plc., Santen Pharmaceutical Co. Ltd., Envisia Therapeutics, pSivida, Clearside Biomedical, Oculis Pharma, Valeant Pharmaceuticals, Aptar Group, Inc., Graybug Vision Inc., Alimera Sciences, Eyegate Pharma, Vision Ophthalmology Group GmbH, URSAPHARM Arzneimittel GmbH, AbbVie Inc., Taiwan Liposome Company, Ltd., Novartis, Amorphex Therapeutics, Eyenovia, Inc., iVeena Delivery Systems, and others.

5. Which region has the highest share in the Ocular Drug Delivery System market?

Among all the regions, North America is estimated to amass a significant revenue share in the global Ocular Drug Delivery System market. This domination is due to the rising prevalence of eye disorders such as cataract, diabetic retinopathy, and others, the increasing geriatric population, and the rising product launches in North America, during the forecast period.

Table of Contents

1. Ocular Drug Delivery System Market Report Introduction

2. Ocular Drug Delivery System Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Ocular Drug Delivery System Market Key Factors Analysis

• 4.1. Ocular Drug Delivery System Market Drivers
  • 4.1.1. The rising prevalence of various eye disorders and problems such as cataract, glaucoma, eye allergies, and infections, among others.
  • 4.1.2. The growing burden of the geriatric population globally
  • 4.1.3. The increasing product developmental activities in the ocular drug delivery systems market.
• 4.2. Ocular Drug Delivery System Market Restraints and Challenges
  • 4.2.1. Side effects associated with the use of eye drops, gels, ointments
  • 4.2.2. Complications involved in ocular surgeries
• 4.3. Ocular Drug Delivery System Market Opportunities
  • 4.3.1. Improving drug delivery safety and biocompatibility
  • 4.3.2. Enhancing formulations for greater drug efficacy and longevity

5. Ocular Drug Delivery System Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Ocular Drug Delivery System Market

7. Ocular Drug Delivery System Market Layout

• 7.1. By Technology
  • 7.1.1. Implantable
  • 7.1.2. Particulate
  • 7.1.3. Others
• 7.2. By Indication
  • 7.2.1. Glaucoma
  • 7.2.2. Cataract
  • 7.2.3. Dry Eyes
  • 7.2.4. Eye Allergy
  • 7.2.5. Others
• 7.3. By Formulation
  • 7.3.1. Solution based
  • 7.3.2. Suspension based
  • 7.3.3. Emulsion based
  • 7.3.4. Others
• 7.4. By Route of Administration
  • 7.4.1. Topical
  • 7.4.2. Intraocular
  • 7.4.3. Intravitreal
  • 7.4.4. Intracameral
  • 7.4.5. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.1.2. Canada Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Ocular Drug Delivery System Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.2.2. Germany Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.2.4. Italy Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.2.5. Spain Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Ocular Drug Delivery System Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.3.2. Japan Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.3.3. India Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.3.4. Australia Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Ocular Drug Delivery System Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.4.2. Africa Ocular Drug Delivery System Market in USD million (2021-2030)
    • 7.5.4.3. South America Ocular Drug Delivery System Market in USD million (2021-2030)

8. Ocular Drug Delivery System Market Company and Product Profiles

• 8.1. Ocular Therapeutix Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Allergan plc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Santen Pharmaceutical Co. Ltd.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Envisia Therapeutics
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. pSivida
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Clearside Biomedical
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Oculis Pharma
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Valeant Pharmaceuticals
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Aptar Group, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Graybug Vision Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Alimera Sciences
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Eyegate Pharma
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Vision Ophthalmology Group GmbH
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. URSAPHARM Arzneimittel GmbH
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. AbbVie Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Taiwan Liposome Company, Ltd.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Novartis
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Amorphex Therapeutics
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Eyenovia, Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. iVeena Delivery Systems
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us